<DOC>
	<DOCNO>NCT01481805</DOCNO>
	<brief_summary>To explore biomarkers predictive clinical response sorafenib unresectable hepatocellular carcinoma use Prometheus Platform To analyze expression activation status receptor tyrosine kinases signal transduction pathway FNA sample circulate tumor cell . To identify negative predictive marker sorafenib . To elucidate signal transduction pathway attributable sorafenib resistance . To monitor change RTK activation status sorafenib treatment use circulate tumor cell . To analyze correlation quantity circulate tumor cell circulate endothelial cell precursor treatment response sorafenib .</brief_summary>
	<brief_title>Biomarker Analysis Sorafenib Treated Hepatocellular Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients histologically confirm hepatocellular carcinoma ( HCC ) combination radiologically compatible find HCC , alphafetoprotein &gt; 400ng/mL liver cirrhosis Inoperable disease define ( Localized disease portion liver dose allow possibility complete surgical removal tumor clear resection margin OR Presence extrahepatic disease OR Main portal vein hepatic vein involvement ( invasion tumor thrombus ) OR The HCC must amenable intraarterial therapy local ablative therapy ) Minimum life expectancy 12 week Age &gt; 18 year . ECOG Performance Status ≤ 2 Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : ( Hemoglobin &gt; 9.0 g/dl , Absolute neutrophil count &gt; 1,500/mm3 , Platelet count &gt; 75,000/μl , Total bilirubin &lt; 1.5 time upper limit normal , ALT AST &lt; 5 x upper limit normal , Albumin ≥ 3g/dL , PTINR/PTT &lt; 1.5 x upper limit normal , Serum creatinine &lt; 1.5 x upper limit normal Creatinine clearance ≥ 50mL/min ) Signed date informed consent start specific protocol procedure . FNA perform patient feasible biopsy site Decompensated cirrhosis stage C ( Index &gt; 10 ) accord ChildPugh Classification Other concomitant anticancer agent , include Tamoxifen Interferon Active clinically serious infection ( &gt; grade 2 CTCAE version 3.0 ) History organ allograft Patients evidence history bleed diasthesis Patients undergoing renal dialysis Radiotherapy study within 4 week start study drug . Prior exposure study drug . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>